Effects of Edaravone on Neurological Function and Tumor Necrosis Factor Alpha and Interleukin 8 Levels in Patients with Cerebral Infarction

Li, Xiushan; Ma, Ding; Sun, Guibo

doi:10.1159/000505776

Cited by 7 publications

(15 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After excluding commentaries, conference abstracts, reviews and meta‐analyses, non‐English articles, non‐SCI studies, and studies not related to the application of edaravone or MCI‐186 in the treatment of stroke, brain infract, cerebral infraction, cerebrovascular disease or brain attack, 25 articles were downloaded for further selection. Finally, 7 studies 18 , 19 , 20 , 21 , 22 , 23 , 24 were included for this meta‐analysis. The flow diagram of the study selection is presented in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…All RCTs focused on the comparison of edaravone plus conventional therapy with routine treatment alone. Three RCTs 18 , 20 , 22 investigated patients with a treatment time window within 24 h, and three RCTs 19 , 21 , 22 investigated patients with stable vital signs who were admitted to hospitals during 24‐72 hours after the onset of stroke. Five RCTs 19 , 21 , 22 , 23 , 24 investigated patients treated with edaravone for two weeks and the other two RCTs included patients treated with edaravone for one week.…”

Section: Resultsmentioning

confidence: 99%

“…Three RCTs 18 , 20 , 22 investigated patients with a treatment time window within 24 h, and three RCTs 19 , 21 , 22 investigated patients with stable vital signs who were admitted to hospitals during 24‐72 hours after the onset of stroke. Five RCTs 19 , 21 , 22 , 23 , 24 investigated patients treated with edaravone for two weeks and the other two RCTs included patients treated with edaravone for one week. Four RCTs 18 , 20 , 21 , 22 evaluated outcome at the long‐term follow‐up, namely three months or later.…”

Section: Resultsmentioning

confidence: 99%

“…Four RCTs 18 , 20 , 21 , 22 evaluated outcome at the long‐term follow‐up, namely three months or later. The other three RCTs 19 , 23 , 24 made an assessment at two weeks follow‐up. The detailed quality assessment of the included studies is presented in Table 2 and Figure 2 .…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta‐analysis of randomized controlled trials

Chen

Lin

et al. 2021

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objective Edaravone is a new antioxidant and hydroxyl radical scavenger. Although there is evidence that it improves clinical outcomes of patients with acute ischaemic stroke (AIS), it is not yet widely accepted for treatment of AIS in Western countries. We further investigated the efficacy and safety of edaravone through this meta‐analysis of randomized controlled clinical trials (RCTs). Method Pubmed, Embase, Web of Science and Cochrane Library were screened up to December 2020 for original articles from SCI journals that published in English. RCTs that compared edaravone versus placebo or no intervention in adult patients and reported the efficacy or safety of edaravone were regarded as eligible. Mortality was regarded as the primary outcome and the improvement of neurological impairment was regarded as the secondary outcome. Safety evaluation was conducted according to the incidence of adverse events. Review Manager 5.3 was employed to perform the assessment of the risk of bias and data synthesis. The Cochrane risk of bias tool for randomized controlled trials was employed to assess the risk of bias. Results and discussion Seven randomized controlled trials with 2069 patients were included. For the incidence of mortality, the pooled RR for studies that evaluated edaravone after three‐month follow‐up was 0.55 (95% Cl, 0.43‐0.7, I2 = 0, P < 0.01). The pooled RR for improvement of neurological impairment at the three months follow‐up was 1.54 (95% CI, 1.27‐1.87, I2 = 0, P < 0.01) in four RCTs. On subgroup analysis of studies that were conducted in Asia, the RR was 1.56 (95% CI, 1.27‐1.90, I2 = 0%; P < 0.01); the pooled RR for studies that conducted in Europe was 1.32 (95% CI, 0.64‐2.72; P = 0.45); the pooled RR for studies that used edaravone for two weeks was 1.42 (95% CI, 1.10 to 1.83, I2 = 0%; P < 0.01); the pooled RR for studies that used edaravone for one week was 1.64 (95% CI, 1.24‐2.16, I2 = 0%; P < 0.01); the pooled RR for studies that conducted in patients with mean age equal to or over 60 years was 1.52 (95% CI, 1.24‐1.87, I2 = 0%; P < 0.01); and the pooled RR for studies that conducted in patients with mean age less than 60 was 1.80 (95% CI, 1.05‐3.08, I2 = 0%; P = 0.03). For the incidence of any treatment‐related adverse events, the pooled RR for studies that evaluated edaravone during treatment was 0.83 (95% CI, 0.51‐1.34, I2 = 0, P = 0.43). The difference of the incidence of any treatment‐related adverse events between two groups was not statistically significant. What is new and conclusion The limited studies indicate that edaravone can improve neurological impairment with a survival benefit at three‐month follow‐up, regardless of the mean age and course of treatment. It is worthy of promotion in the clinical treatment of AIS in Asian countries. More well‐designed RCTs with larger sample sizes are needed to determine the benefits of edaravone in patients from Western countries.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta‐analysis of randomized controlled trials

Chen

Lin

et al. 2021

J Clin Pharm Ther

View full text Add to dashboard Cite

show abstract

“…Butylphthalide injection can exert anti-apoptosis; improve mitochondrial function, anti-inflammatory, and other effects through the blood-brain barrier; and ultimately improve the function of nerve cells. In the clinical treatment of ACI, butylphthalide sodium chloride injection has been widely used and shows remarkable effects [ 16 , 17 ]. In this study, Fuyuan Xingshen Decoction combined with butylphthalide sodium chloride injection was given to the observation group to observe the clinical effect.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Fuyuan Xingshen Decoction Combined with Butylphthalide Sodium Chloride Injection in the Treatment of Acute Cerebral Infarction and Its Effect on Hemodynamics

Zhang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. This study aims to determine the curative effect of Fuyuan Xingshen Decoction combined with butylphthalide sodium chloride injection in acute cerebral infarction (ACI) treatment and its effect on hemodynamics. Methods. In our hospital, a total of 84 ACI patients from May 2020 to February 2022 were randomly divided into two groups: observation and control (n = 42 each). Fuyuan Xingshen Decoction in combination with butylphthalide sodium chloride injection was provided to the observation group, while the control group received butylphthalide sodium chloride injection alone. Both groups’ clinical efficacy was observed. Before and after treatment, the neurological function of the two groups was evaluated using the National Institutes of Health Stroke Scale (NIHSS), while the daily living ability of both groups was determined using the Barthel index rating scale. Both groups were investigated for their cognitive function, before and after treatment, by using the Mini-Cog scale and Montreal Cognitive Assessment (MoCA) scale. The pulsatility index (PI), peak velocity (Vp), and mean velocity (Vm) of intracranial arteries were measured by transcranial Doppler ultrasonography before and after treatment. The levels of ubiquitin carboxy-terminal hydrolase-1 (UCH-L1), Fibulin-5, and visinin-like protein-1 (VILIP-1) in serum and the expression levels of miR-34c, miR-25, and miR-182 in peripheral blood of the two groups were compared. Both groups were observed for the incidence of adverse reactions. Results. Compared with the control (71.43%), the observation group exhibited a significantly higher effective rate of around 90.48%. In the observation group, the improvement in NIHSS, Barthel index, Mini-cog, and MoCA scores; hemodynamic indexes including Vp, PI, and Vm; serum UCH-L1, Fibulin-5, and VILIP-1 levels; and the miR-34c, miR-25, and miR-182 expression levels in peripheral blood was better than the control group, with significant difference (all P < 0.05 ). The incidence of adverse reactions between the groups demonstrated no significant differences ( P > 0.05 ). Conclusions. Fuyuan Xingshen Decoction combined with butylphthalide sodium chloride injection can effectively improve patients’ daily living ability, neurological function, cognitive function, and cerebral hemodynamics in the treatment of ACI, with good effect and safety.

show abstract

Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis

Zhao¹,

Li²,

Ye³

et al. 2022

Clinical Therapeutics

View full text Add to dashboard Cite

Effects of Edaravone on Neurological Function and Tumor Necrosis Factor Alpha and Interleukin 8 Levels in Patients with Cerebral Infarction

Cited by 7 publications

References 23 publications

Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta‐analysis of randomized controlled trials

Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta‐analysis of randomized controlled trials

Efficacy of Fuyuan Xingshen Decoction Combined with Butylphthalide Sodium Chloride Injection in the Treatment of Acute Cerebral Infarction and Its Effect on Hemodynamics

Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About